share_log

开源证券4月25日发布研报称，给予药石科技（300725.SZ）买入评级。评级理由主要包括：1）多因素导致利润端承压，服务客户数量持续增加；2）以市场需求为导向，设计一系列新化学实体药物研发所需要的分子砌块；3）CDMO管线不断拓展，产能建设稳健推进，持续赋能全球客户。（每日经济新闻）

Open Source Securities released a research report on April 25 stating that it gave Yakishi Technology (300725.SZ) a purchase rating. The main reasons for the rating include: 1) the profit side is under pressure due to multiple factors, and the number of s

Zhitong Finance ·  Apr 26 12:24
Open Source Securities released a research report on April 25 stating that it gave Yakishi Technology (300725.SZ) a purchase rating. The main reasons for the rating include: 1) the profit side is under pressure due to multiple factors, and the number of service customers continues to increase; 2) the design of a series of molecular blocks required for the development of new chemical physical drugs based on market demand; 3) the CDMO pipeline continues to expand, production capacity construction progresses steadily, and continues to empower global customers. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment